Are There Treatments Targeting Oncogenic Fusion Proteins?
Yes, targeting oncogenic fusion proteins is a promising therapeutic strategy. Tyrosine kinase inhibitors (TKIs) are drugs that can specifically inhibit the kinase activity of fusion proteins like BCR-ABL. The success of imatinib in treating chronic myeloid leukemia highlights the therapeutic potential of this approach. Similarly, inhibitors targeting the ALK fusion protein in lung cancer, such as crizotinib, have shown significant clinical benefits.
